Skip to content

Therapeutic Effect of Back-shu Point Catgut Embedding in Spleen-stomach Deficiency Type I and II Myasthenia Gravis

Therapeutic Effect of Back-shu Point Catgut Embedding in Spleen-stomach Deficiency Type I and II Myasthenia Gravis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002613
Enrollment
Unknown
Registered
2019-09-22
Start date
2019-09-23
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis

Interventions

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with Myasthenia Gravis based on the diagnostic criteria of Practical internal science (Peoples Medical Publishing House The 15th edition)and patients with MG belonging to the the modifed Osseman III type; 2. Diagnosed with Chinese medical diagnosis of flaccidity fitting to the differentiation standard of spleen-stomach deficiency type; 3. Aged 18 to 75-year-old; 4. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Osseman III, IV, V; 2. Familial MG, congenital myasthenic syndrome and drug (D-penicillamine, interferon induced by MG, etc.); 3. Patients who were nursing or pregnant; 4. Patients who had comorbid diseases such as cerebrovascular diseases, renal insufficiency, hematopoietic system diseases, and psychiatric diseases; 5. Patients who has contraindications for embedding; 6. Allergies (allergic to more than 2 kinds of food or medicine); 7. The last 3 months participated in other clinical trials of drugs.

Design outcomes

Primary

MeasureTime frame
MG-ADL grade;TCM Syndrome Efficacy Criteria scores;MGC scores;MG-QOL15;

Countries

China

Contacts

Public ContactZhuang Lixing

Department of Acupuncture, The First Affiliated Hospital of Guangzhou University of Chinese Medicine

zhuanglixing@163.com+86 13822287775

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026